Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Ceenu

Last reviewed on RxList: 7/27/2020
Ceenu Side Effects Center

What Is CeeNU?

CeeNU (lomustine) is a cancer (antineoplastic) medication used to treat brain tumors and Hodgkin's disease, and is sometimes given with other cancer medications.

What Are Side Effects of CeeNU?

Common side effects of CeeNU include:

Nausea and vomiting usually last for less than 24 hours, though loss of appetite can last for several days.

Dosage for CeeNU

The recommended dose of CeeNU in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m² as a single oral dose every 6 weeks.

What Drugs, Substances, or Supplements Interact with CeeNU?

CeeNU may interact with "live" vaccines. Tell your doctor all medications and supplements you use, and all vaccines you have recently received.

CeeNU During Pregnancy and Breastfeeding

During pregnancy, CeeNU should be used only when prescribed. It may harm a fetus. If you become pregnant or think you may be pregnant, inform your doctor. Women should use 2 forms of birth control while using this medication. Consult your doctor. It is unknown if this drug passes into breast milk. Breastfeeding while using this drug is not recommended.

Additional Information

Our CeeNU (lomustine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow
Ceenu Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • jaundice (yellowing of the skin or eyes);
  • easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
  • signs of infection--fever, chills, sore throat, blisters or ulcers in your mouth, red or swollen gums, trouble swallowing;
  • kidney problems--confusion, little or no urinating; swelling in your feet or ankles; feeling tired or short of breath; or
  • low red blood cells (anemia)--pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating.

Late-onset lung damage has occurred in some adults who had been treated for brain tumors during childhood. These patients had been treated with both radiation and medicine similar to lomustine. Lung symptoms developed up to 17 years after treatment. Call your doctor at once if you have:

  • chest discomfort, dry cough or hack;
  • shortness of breath on exertion; or
  • weakness or tired feeling, loss of appetite, and rapid weight loss.

Common side effects may include:

  • nausea, vomiting;
  • delayed infection;
  • mouth sores; or
  • temporary hair loss.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Ceenu (Lomustine Capsules)

Ceenu Professional Information

SIDE EFFECTS

Hematologic Toxicity

The most frequent and most serious toxicity of CeeNU is delayed myelosuppression. It usually occurs 4 to 6 weeks after drug administration and is dose related. Thrombocytopenia occurs at about 4 weeks postadministration and persists for 1 to 2 weeks. Leukopenia occurs at 5 to 6 weeks after a dose of CeeNU and persists for 1 to 2 weeks. Approximately 65% of patients receiving 130 mg/m² develop white blood counts below 5000 wbc/mm³. Thirty-six percent developed white blood counts below 3000 wbc/mm³. Thrombocytopenia is generally more severe than leukopenia. However, both may be dose-limiting toxicities.

CeeNU may produce cumulative myelosuppression, manifested by more depressed indices or longer duration of suppression after repeated doses.

The occurrence of acute leukemia and bone marrow dysplasias have been reported in patients following long-term nitrosourea therapy.

Anemia also occurs, but is less frequent and less severe than thrombocytopenia or leukopenia.

Pulmonary Toxicity

Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported rarely with CeeNU. Onset of toxicity has occurred after an interval of 6 months or longer from the start of therapy with cumulative doses of CeeNU usually greater than 1100 mg/m². There is 1 report of pulmonary toxicity at a cumulative dose of only 600 mg.

Delayed onset pulmonary fibrosis occurring up to 17 years after treatment has been reported in patients who received related nitrosoureas in childhood and early adolescence (1-16 years) combined with cranial radiotherapy for intracranial tumors. There appeared to be some late reduction of pulmonary function of all long-term survivors. This form of lung fibrosis may be slowly progressive and has resulted in death in some cases. In this long-term study of carmustine, all those initially treated at less than 5 years of age died of delayed pulmonary fibrosis.

Gastrointestinal Toxicity

Nausea and vomiting may occur 3 to 6 hours after an oral dose and usually last less than 24 hours. Prior administration of antiemetics is effective in diminishing and sometimes preventing this side effect. Nausea and vomiting can also be reduced if CeeNU is administered to fasting patients.

Hepatotoxicity

A reversible type of hepatic toxicity, manifested by increased transaminase, alkaline phosphatase, and bilirubin levels, has been reported in a small percentage of patients receiving CeeNU.

Nephrotoxicity

Renal abnormalities consisting of progressive azotemia, decrease in kidney size, and renal failure have been reported in patients who received large cumulative doses after prolonged therapy with CeeNU. Kidney damage has also been reported occasionally in patients receiving lower total doses.

Other Toxicities

Stomatitis, alopecia, optic atrophy, and visual disturbances, such as blindness, have been reported infrequently.

Neurological reactions, such as disorientation, lethargy, ataxia, and dysarthria have been noted in some patients receiving CeeNU. However, the relationship to medication in these patients is unclear.

Read the entire FDA prescribing information for Ceenu (Lomustine Capsules)

Related Resources for Ceenu

© Ceenu Patient Information is supplied by Cerner Multum, Inc. and Ceenu Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow

Health Solutions From Our Sponsors